155 related articles for article (PubMed ID: 3144551)
1. In-vitro activity of fleroxacin against Chlamydia trachomatis.
Steele-Mortimer O; Meier-Ewert H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():65-70. PubMed ID: 3144551
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.
Walsh M; Kappus EW; Quinn TC
Antimicrob Agents Chemother; 1987 May; 31(5):811-2. PubMed ID: 3038010
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis.
Nagayama A; Nakao T; Taen H
Antimicrob Agents Chemother; 1988 Nov; 32(11):1735-7. PubMed ID: 3150916
[TBL] [Abstract][Full Text] [Related]
4. [Susceptibility study on urogenital Chlamydia trachomatis to 19 kinds of antibiotics].
Bai H; Dong J; Ning B
Zhonghua Yi Xue Za Zhi; 1995 Jan; 75(1):11-4, 60. PubMed ID: 7600311
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.
Furneri PM; Bazzano M; Campo L; Cesana M; Tempera G
Chemotherapy; 1994; 40(2):104-8. PubMed ID: 8131632
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of fleroxacin.
Georgopoulos A; Breyer S; Georgopoulos M; Mailer H; Graninger W
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():25-9. PubMed ID: 3144544
[TBL] [Abstract][Full Text] [Related]
7. Chlamydia trachomatis: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin.
Børsum T; Dannevig L; Størvold G; Melby K
Chemotherapy; 1990; 36(6):407-15. PubMed ID: 1963393
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin.
Pohlod DJ; Saravolatz LD; Somerville MM
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():49-54. PubMed ID: 3144549
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.
Maeda H; Fujii A; Nakata K; Arakawa S; Kamidono S
Antimicrob Agents Chemother; 1988 Jul; 32(7):1080-1. PubMed ID: 2847640
[TBL] [Abstract][Full Text] [Related]
10. Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.
Wagner J; Jabbusch M; Eisenblätter M; Hahn H; Wendt C; Ignatius R
Antimicrob Agents Chemother; 2003 Jul; 47(7):2358-61. PubMed ID: 12821499
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of tetracycline & ciprofloxacin against Chlamydia trachomatis isolates from conjunctivitis patients.
Madhavan HN; Roy S; Malathy J
Indian J Med Res; 1996 Mar; 103():138-41. PubMed ID: 9062038
[TBL] [Abstract][Full Text] [Related]
12. Chlamydia trachomatis: in vitro susceptibility to antibiotics singly and in combination.
Christensen JJ; Holten-Andersen W; Nielsen PB
Acta Pathol Microbiol Immunol Scand B; 1986 Oct; 94(5):329-32. PubMed ID: 3788573
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.
Welsh LE; Gaydos CA; Quinn TC
Antimicrob Agents Chemother; 1992 Feb; 36(2):291-4. PubMed ID: 1318677
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.
Samra Z; Rosenberg S; Soffer Y; Dan M
Diagn Microbiol Infect Dis; 2001 Mar; 39(3):177-9. PubMed ID: 11337185
[TBL] [Abstract][Full Text] [Related]
15. An in-vitro investigation of synergy and antagonism between antimicrobials against Chlamydia trachomatis.
How SJ; Hobson D; Hart CA; Webster RE
J Antimicrob Chemother; 1985 May; 15(5):533-8. PubMed ID: 4008386
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study of minimal inhibitory concentration (MIC) and minimal lethal concentration (MLC) values for tetracycline, monocycline, erythromycin and rokitamycin against eleven strains of Chlamydia trachomatis].
Bianchi A; Scieux C; Robache S; Vassias I; Pérol Y
Pathol Biol (Paris); 1991 May; 39(5):442-5. PubMed ID: 1881673
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Chlamydia trachomatis to trovafloxacin.
Jones RB; Van der Pol B; Johnson RB
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():63-5. PubMed ID: 9222072
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
J Antimicrob Chemother; 1999 Oct; 44(4):549-51. PubMed ID: 10588319
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and tolerance of fleroxacin in patients with urethritis caused by Chlamydia trachomatis.
Pust RA; Ackenheil-Köppe HR; Weidner W; Meier-Ewert H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():227-30. PubMed ID: 3144543
[TBL] [Abstract][Full Text] [Related]
20. Anti-Brucella activity of Ro 23-9424, a dual-action antibacterial.
Qadri SM; Ueno Y; Ayub A
Chemotherapy; 1993; 39(6):386-9. PubMed ID: 8222864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
